• 1
    National High Blood Pressure Education Program (NHBPEP). Working Group Report on High Blood Pressure in Pregnancy. Washington : US Department of Health and Human Services; 1991. Bethesda, Maryland, USA. National Institutes of Health Publication No. 91–3029.
  • 2
    Poston L. Maternal vascular function in pregnancy. J Hum Hypertens 1996; 10: 391394.
  • 3
    Cheung CY. Vascular endothelial growth factor: possible role in fetal development and placental function. J Soc Gynecol Invest 1997; 4: 169177.
  • 4
    Torry DS, Torry RJ. Angiogenesis and the expression of vascular endothelial growth factor in endometrium and placenta. Am J Reprod Immunol 1997; 37: 2129.
  • 5
    Taylor CM, Stevens H, Anthony FW, T Wheeler. Influence of hypoxia on vascular endothelial growth factor and chorionic gonadotrophin production in the trophoblast-derived cell lines: JEG, JAr and BeWo. Placenta 1997; 18: 451458.
  • 6
    Evans P, Wheeler T, Anthony F, Osmond C. Maternal serum vascular endothelial growth factor during early pregnancy. Clin Sci 1997; 92: 567571.
  • 7
    Anthony FW, Evans PW, Wheeler T, Wood PJ. Variation in detection of VEGF in maternal serum by immunoassay and the possible influence of binding proteins. Ann Clin Biochem 1997; 34: 276280.
  • 8
    Baker PN, Krasnow J, Roberts JM, Yeo K. Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia. Obstet Gynecol 1995; 86: 815821.
  • 9
    Sharkey AM, Cooper JC, Balmforth JR et al. Maternal plasma levels of vascular endothelial growth factor in normotensive pregnancies and in pregnancies complicated by pre-eclampsia. Eur J Clin Invest 1996; 26; 11821185.
  • 10
    Kupferminc MJ, Daniel Y, Englender T et al. Vascular endothelial growth factor is increased in patients with preeclampsia. Am J Reprod Immunol 1997; 38: 302306.
  • 11
    Lyall F, Greer IA, Boswell F, Fleming F. Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and preeclampsia. Br J Obstet Gynaecol 1997; 104: 223228.
  • 12
    Lyall F, Young A, Boswell B, Kingdom JCP, Greer IA. Placental expression of vascular endothelial growth factor in placentas from pregnancies complicated by pre-eclampsia and intrauterine growth restriction does not support placental hypoxia at delivery. Placenta 1997; 18: 269276.
  • 13
    Chappell L, Bewley S. Pre-eclamptic toxaemia: the role of uterine artery Doppler. Br J Obstet Gynaecol 1998; 105: 379382.
  • 14
    Australasian Society for the Study of Hypertension in Pregnancy. Management of Hypertension in Pregnancy Consensus Statement. Sydney : Australia . Australasian Society for the Study of Hypertension in Pregnancy, 1993.
  • 15
    Irion O, Massé J, Forest J, Moutquin J. Prediction of pre-eclampsia, low birthweight for gestation and prematurity by uterine artery blood flow velocity waveforms analysis in low risk nulliparous women. Br J Obstet Gynaecol 1998; 105: 422429.
  • 16
    North RA, Ferrier C, Long D, Townend K, Kincaid-Smith P. Uterine artery Doppler flow velocity waveforms in the second trimester in the prediction of preeclampsia and fetal growth retardation. Obstet Gynecol 1994; 83: 378386.
  • 17
    Hara N, Fujii T, Yamashita T, Kozuma S, Okai T, Taketani Y. Altered expression of human leukocyte antigen G (HLA-G) on extravillous trophoblasts in preeclampsia: immunohistological demonstration with anti-HLA-G specific antibody ‘87 G’ and anti-cytokeratin antibody ‘CAM5.2’. Am J Reprod Immunol 1996; 36: 349358.
  • 18
    Santa Cruz Biotechnology Inc, Research Antibodies 1997/1998. Santa Cruz Biotechnology Inc, Santa Cruz , California , USA . VEGF/PIGF angiogenic factors: 243245.
  • 19
    Hennessy A, Pilmore HL, Simmons LA, Painter DM. A deficiency of placental interleukin-10 in preeclampsia. Am J Immunol 1999; 163: 34913495.
  • 20
    Cooper JC, Sharkey AM, Charnock-Jones DS, Palmer CR, Smith SK. VEGF mRNA levels in placentae from pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol 1996; 103: 11911196.
  • 21
    Reuvekamp A, Velsing-Aarts FV, Poulina IEJ, Capello JJ, Duits AJ. Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol 1999; 106: 10191022.
  • 22
    Murohara T, Horowitz JR, Silver M et al. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 1998; 97: 99107.
  • 23
    Papapetropoulos A, García-Cardeña G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997; 100: 31313139.
  • 24
    Yang R, Thomas GR, Bunting S et al. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol 1996; 27: 838844.
  • 25
    Hoffman BB, Lefkowitz RJ. Catecholamines and sympathomimetic drugs. In: Goodman GilmanA, RallTW, NiesAS, TaylorP, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics Eighth Edition. Singapore : McGraw-Hill, 1992; 208210.
  • 26
    David R, Leitch IM, Read MA, Boura ALA, Walters WAW. Actions of magnesium, nifedipine and clonidine on the fetal vasculature of the human placenta. Aust N Z J Obstet Gynaecol 1996; 36: 267271.
  • 27
    Gudmundsson S, Gennser G, Marsal K. Effects of hydralazine on placental and renal circulation in pre-eclampsia. Acta Obstet Gynecol Scand 1995; 74: 415418.
  • 28
    Pearce JM, Campbell S, Cohen-Overbeek T, Hackett G, Hernandez J, Royston JP. Reference ranges and sources of variation for indices of pulsed Doppler flow velocity waveforms from the uteroplacental and fetal circulation. Br J Obstet Gynaecol 1988; 95: 248256.